title: Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
abstract: Glucagon-like peptide 1 receptor (GLP1R) signaling has been shown to have antipsychotic properties in animal models and to impact glucose-dependent insulin release, satiety, memory, and learning in man. Previous work has shown that two coding mutations (rs6923761 and rs1042044) are associated with altered insulin release and cortisol levels. We identified four frequently occurring haplotypes in Caucasians, haplotype 1 through haplotype 4, spanning exons 4-7 and containing the two coding variants. We analyzed response to antipsychotics, defined as predicted change in PANSS-Total (dPANSS) at 18 months, in Caucasian subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness treated with olanzapine (n=139), perphenazine (n=78), quetiapine (n=14), risperidone (n=143), and ziprasidone (n=90). Haplotype trend regression analysis revealed significant associations with dPANSS for olanzapine (best p=0.002), perphenazine (best p=0.01), quetiapine (best p=0.008), risperidone (best p=0.02), and ziprasidone (best p=0.007). We also evaluated genetic models for the two most common haplotypes. Haplotype 1 (uniquely including the rs1042044 [Leu(260)] allele) was associated with better response to olanzapine (p=0.002), and risperidone (p=0.006), and worse response to perphenazine (p=.03), and ziprasidone (p=0.003), with a recessive genetic model providing the best fit. Haplotype 2 (uniquely including the rs6923761 [Ser(168)] allele) was associated with better response to perphenazine (p=0.001) and worse response to olanzapine (p=.02), with a dominant genetic model providing the best fit. However, GLP1R haplotypes were not associated with antipsychotic-induced weight gain. These results link functional genetic variants in GLP1R to antipsychotic response.
authors.affiliation: SureGene, LLC, 600 Envoy Circle, Louisville, KY 40299, USA.
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Ramsey
authors.affiliation: SureGene, LLC, 600 Envoy Circle, Louisville, KY 40299, USA. Electronic address: mark.brennan@suregene.net.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Brennan
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D060005:Genotyping Techniques; D000067757:Glucagon-Like Peptide-1 Receptor; D006239:Haplotypes; D006801:Humans; D008297:Male; D008957:Models, Genetic; D000077152:Olanzapine; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D000069348:Quetiapine Fumarate; D018027:Receptors, Glucagon / Q000235:genetics*; D012044:Regression Analysis; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects / Q000235:genetics; D044465:White People / Q000235:genetics
chemical_list: D014150:Antipsychotic Agents; D054316:Biomarkers, Pharmacological; D003987:Dibenzothiazepines; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D010879:Piperazines; D018027:Receptors, Glucagon; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D010546:Perphenazine; D018967:Risperidone; D000077152:Olanzapine
keywords: Olanzapine; Perphenazine; Pharmacogenetics; Quetiapine; Risperidone; Schizophrenia; Ziprasidone